At first I was, but then took them out. Maybe I can get my point across now:
Interesting that Bristol-Meyers-Squibb looks like a good fit:
1. One of the authors of the JCO article, Jane Liesveld, received research funding from Bristol-Meyers-Squibb
2. Talon's Chairman of the board, Leon E. Rosenberg, M.D., resume reads "From January 1997 to March 1998, Dr. Rosenberg served as Senior Vice President, Scientific Affairs of Bristol-Myers Squibb Company, and from September 1991 to January 1997, Dr. Rosenberg served as President of the Bristol-Myers Squibb Pharmaceutical Research Institute."
3. Howard Pien, also a board member of Talon's resume reads "Mr. Pien was most recently employed at Medarex, Inc. serving as President, Chief Executive Officer, and Chairman of the Board until Bristol-Myers Squibb acquired it in 2009."
4. From Bristol-Meyers-Squibb Web page, in Therapeutic Areas of Focus, Oncology
"Cancer represents a multitude of diseases. We concentrate our efforts on cancer types where the unmet medical needs, as measured by gaps in current therapies and the magnitude of the burden on public health, are especially high. These include lung cancer, prostate cancer, melanoma, gastrointestinal cancer and hematologic cancers."